Abstract
Candida is a leading cause of late onset infection (> 3 days of age) in the premature infant. Therefore, decisions about the diagnosis and management of infections caused by Candida are commonplace in the neonatal intensive care unit. Despite this fact, there are few comparative trials about treatment of neonatal Candida infections to guide the practitioner. New antifungals have been developed in the past decade and some clinical experience has been reported that can be used to guide the treatment of infants with serious Candida infections. This article reviews recent pertinent data with regard to dosing guidelines, efficacy, and toxicities of available systemic antifungal agents in the newborn.
MeSH terms
-
Amphotericin B / therapeutic use
-
Antifungal Agents / therapeutic use*
-
Candidiasis / drug therapy*
-
Caspofungin
-
Cross Infection / drug therapy*
-
Echinocandins
-
Fluconazole / therapeutic use
-
Flucytosine / therapeutic use
-
Fungal Proteins*
-
Fungemia / drug therapy*
-
Humans
-
Infant, Newborn
-
Infant, Premature
-
Intensive Care Units, Neonatal
-
Ketoconazole / therapeutic use
-
Lipopeptides
-
Peptides / therapeutic use
-
Peptides, Cyclic*
-
Pyrimidines / therapeutic use
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Fungal Proteins
-
Lipopeptides
-
Peptides
-
Peptides, Cyclic
-
Pyrimidines
-
Triazoles
-
Amphotericin B
-
Fluconazole
-
echinocandin B
-
Flucytosine
-
Caspofungin
-
Voriconazole
-
Ketoconazole